Data emerging from upcoming clinical trials assessing the treatment efficacy in people with clinically established Parkinson’s disease will shed light on optimal treatment approaches. In this interview with touchNEUROLOGY, Prof. Angelo Antonini (IRCCS San Camillo, Venice, and University of Padova, Italy) gives his thoughts on these and discusses how new efficacious therapies for Parkinson’s disease may be used most effectively.
Questions:
- Upcoming trials will assess treatment efficacy in people with clinically established Parkinson’s disease; why might this approach not be optimal in understanding potential disease modification? (00:15)
- As efficacious therapies become available for Parkinson’s disease, how can they be used most effectively in improving disease outcomes for patients? (08:40)
The abstract titled ‘Update on disease-modifying treatments’ (Abstract #SYMP01-4) was presented at the European Academy of Neurology Congress 2022, 25–28 June 2022.
Disclosures: Angelo Antonini has served as a consultant for: AbbVie, UCB, Britannia; participated in advisory boards for Jazz Pharmaceutical, Bial; and received honoraria from Bial and Zambon
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of EAN 2022.
